Y.ora Vision Launches with Novel MIGS Device for Glaucoma Treatment Following SERI-Eyexora Licensing Deal
核心洞察
Y.ora Vision (搜索) has launched following a licensing agreement between Singapore Eye Research Institute (SERI) and Eyexora (搜索) Global to advance a minimally invasive glaucoma surgery device.
The company's proprietary YRA-01 (搜索) platform is a handheld MIGS device designed to perform multiple trabeculotomies for mild-to-severe open-angle glaucoma in under 10 minutes.
The technology addresses a significant unmet need as glaucoma affects more than 80 million people globally and remains the leading cause of irreversible blindness.
Y.ora Vision (搜索), Inc., a new ophthalmic medical device company and spoke company of Eyexora (搜索), has launched following the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a minimally invasive surgical device for treating mild-to-severe open-angle glaucoma.
Novel MIGS Technology Platform
The licensed technology, developed by SERI researchers and co-inventors Associate Professor Shamira Perera and Professor Michael Belkin, forms the foundation of Y.ora Vision (搜索)'s proprietary platform (YRA-01 (搜索)). This minimally invasive surgical (MIGS) device is designed to perform multiple trabeculotomies for mild-to-severe Open Angle Glaucoma (OAG), representing a next-generation surgical approach designed to lower intraocular pressure (IOP) safely and effectively without requiring permanent implants.
YRA-01 (搜索) is a handheld device that leverages common equipment in the ophthalmic surgical suite and has the potential to lower IOP in a procedure that can be completed in under 10 minutes while delivering real-time feedback for surgeons. The extent of IOP lowering can potentially be determined by the number of penetrations created, and the procedure has the potential to be repeated.
Addressing Critical Unmet Medical Need
Glaucoma remains the leading cause of irreversible blindness globally, affecting more than 80 million people, with 70% diagnosed with primary open-angle glaucoma (POAG). Current surgical treatment options often fall short due to high costs, safety risks, steep learning curves, limited availability and limited efficacy.
"Glaucoma continues to rob millions of their sight despite decades of therapeutic and device-based advances," said Huan Sheng, MD, PhD, Chief Medical Officer, Eyexora (搜索). "Our goal is to empower all ophthalmic surgeons with a reliable, minimally invasive, and user-friendly tool that achieves meaningful pressure reduction without the complications or cost of traditional implants. We have designed it with the expectation that surgeons will experience a short learning curve, enabling them to more confidently offer this solution to their patients."
SERI Research Foundation
The technology originated from collaborative research at SERI, one of the world's leading ophthalmic research institutions. "This innovation builds upon years of work at SERI as well as clinical expertise in MIGS and reflects our commitment to translational research that directly improves patient outcomes and delivers a very forgiving surgery that is easily accessible to anyone who can perform phacoemulsification," said Associate Professor Shamira Perera, MD, Co-Inventor and Head & Senior Consultant, Glaucoma Department, Singapore National Eye Centre.
"The simplicity of the device enables precise and easy tissue removal with collateral minimal trauma, making it a compelling new option for glaucoma surgeons, cataract surgeons and patients," Perera added.